Pricing Debate
Weight loss drugs have likely proven to be the most challenging medicines to introduce to the National Health Service in England, and lessons should be learned in preparation for other game changing products.
The EU remains a major global player in biopharma but needs to act quickly or risk falling further behind its rivals, according to EFPIA.
A Senate report finds GSK’s withdrawal of Flovent and shift to an authorized generic increased costs, restricted access and disrupted asthma care, while helping the company avoid Medicaid rebates, raising broader concerns over pricing loopholes.
The EU remains a major global player in biopharma but needs to act quickly or risk falling further behind its rivals, according to EFPIA.
A new survey of French healthcare professionals reveals concerns that France is increasingly being excluded from major international clinical studies.
Norway’s pharmaceutical industry association says it is waiting to hear from the ministry of health about how it will address the country’s low willingness to pay for innovation.
European pricing and reimbursement processes, including in the UK, are on hold for now.
Executives from Novo Nordisk, Ipsen, Astellas, Acadia and Flagship Pioneering agree: the dealmaking environment is improving but the calculus has changed. Flexible structures, sharper therapeutic focus, and the long shadow of patent cliffs and pricing policy are reshaping how partnerships get done.
Revelations about a big underspend on England’s Innovative Medicines Fund for promising new non-oncology medicines have prompted calls for more transparency about how the money is allocated and how the fund is administered.
The Pink Sheet’s investigation into England’s Innovative Medicines Fund has prompted calls for change from patients and industry representatives.
The US Most Favored Nation pricing policy that references Danish drug prices is making companies think twice about investing in R&D in the country and risks Denmark’s status as an important “life sciences nation,” according to Lif, the Danish pharmaceutical industry association.
Samsung Bioepis’ Ospomyv and Celltrion’s Stoboclo will be preferred on major US commercial formularies from April 2026, as CVS Caremark drops Prolia and another higher-cost brand, Forteo (teriparatide), to drive savings.